HONG KONG, June 23, 2011 /PRNewswire-Asia/ -- Golden
Meditech Holdings Limited ("Golden Meditech" or the "Group," -
801.HK; 910801.TW), China's
leading integrated healthcare enterprise, today announced that the
Group has accumulated 754,791 ordinary shares in its NYSE-listed
affiliate, China Cord Blood Corporation ("CCBC," - CO.US) from the
open market between December 2010 and
March 2011. As a result of which the
Group now owns 39.5% of the issued share capital of CCBC.
CCBC is the largest cord blood banking operator in China and is the only one with multiple
exclusive operating licenses including Beijing Municipal,
Guangdong Province and
Zhejiang Province, with
approximately 20% stake in the exclusive operator in Shandong Province. Moreover, CCBC also
has a strategic interest and single largest shareholding in
"Cordlife," the largest cord blood banking operator in Asia Pacific markets.
Mr. Kam YUEN, Chairman and Chief Executive Officer of the Group,
said, "We are proud to see that CCBC has sustained strong steady
growth and profitability in its initial markets in Beijing and Guangdong while continuously deliver positive
news on new market expansions since its initial public offering.
As the founding and largest shareholder of CCBC, we remain
optimistic of CCBC's prospects in both China and Asia
Pacific and are duly confident in the capability of its
management team."
CCBC reported strong revenue growth of 29.8% at RMB340 million for the fiscal year ended
March 31, 2011 and a gross margin of
77.2%, while profit attributable to shareholders increased by 86.5%
at RMB91.7 million under US GAAP.
Under the "one-license-per-region" regulatory framework, the
government has issued seven exclusive operating licenses thus far.
The strategic coverage of CCBC's current operation in
Beijing, Shangdong, Zhejiang and Guangdong has enabled it to capture four key
strategic economic strongholds in the affluent eastern coastline of
China, with a combined annual
birth rate totaling 29 million.
Mr. Kam highlighted, "We see considerable room for CCBC to
further enhance market penetration with steady growth and market
development. Its potential and profitability prospects remain
impressive."
About Golden Meditech Holdings Limited
Golden Meditech Holdings Limited is China's leading integrated-healthcare device
and service operator, and the first medical device enterprise that
was publicly listed outside of the PRC on the Stock Exchange of
Hong Kong Limited (HKEx). Golden Meditech is a first-mover in
China, having established dominant
positions in medical devices and healthcare services markets over
the years, thanks to its strengths in innovation and market
expertise and the ability to capture emerging market opportunities.
Going forward, the Group will continue to pursue a leading
position in China's healthcare
industry both through organic growth and strategic expansion.
For enquiries, please contact:
Investor Relations Department
|
|
Golden Meditech Holdings
Limited
|
|
Address:
|
48/F, Bank of China Tower, 1
Garden Road, Central, Hong Kong
|
|
Tel:
|
+852-3605-8180
|
|
Fax:
|
+852-3605-8181
|
|
Email:
|
ir@goldenmeditech.com
|
|
|
|
|
|
SOURCE Golden Meditech Holdings Limited